Short answer
NOVAVAX INC (NVAX) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $140M (down 79.1% year over year) with net income of −$9M.
Q1 2026 key financials · XBRL
- Revenue
- $140M
- −79.1% YoY
- Net income
- −$9M
- −101.8% YoY
- Operating margin
- -11.1%
- EPS (diluted)
- −$0.06
- −102.0% YoY
Source: XBRL data from the NOVAVAX INC (NVAX) Q1 2026 10-Q on SEC EDGAR. USD.
NOVAVAX INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Best or worst-performing segment/product line not identified with quarterly figures
- Pfizer partnership generated $30 million upfront payment in Q1 2026
- Potential Pfizer milestones up to $500 million and high-mid-single-digit royalties, with commercialization headwinds including vaccine demand and regulatory uncertainty
Risk Factors
- No risk-factors section provided in the filing excerpt
- New financing agreement dated February 25, 2026 identified in exhibits
- Pfizer license agreement dated January 14, 2026 identified in exhibits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NOVAVAX INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.